Detalhe da pesquisa
1.
High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.
Cancer Immunol Res
; 12(4): 462-477, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38345397